摘要
目的：观察国产奈达铂联合其他化疗药物治疗非小细胞肺癌的疗效及不良反应。方法：38例晚期非小细胞肺癌患者，采用奈达铂联合吉西他滨或紫杉醇静脉化疗，其中奈达铂80～100mg／m^2，加入500ml生理盐水静滴2h，吉西他滨1000mg／m^2静注，紫杉醇175mg／m^2静滴3h，每3～4周重复。结果：38例病人共化疗98个疗程，平均每例病人化疗2．57个疗程，其中PR13例（34．2％），无CR患者。白细胞下降率约36．8％（14／38），无1例发生肾功能毒性。结论：奈达铂对非小细胞肺癌疗效与顺铂相近，胃肠道毒性轻微，无明显肾毒性，临床上值得进一步推广应用。
Objective： To observe the efficacy and the side effects of domestic nedaplatin in treatment of non - small cell lung cancer （NSCLC）. Method： 38 patients of advanced NSCLC, nedaplatin was administered at a dose of 80～100mg/m^2, with 500ml of saline by slow drip infusion for 120 minutes, gemzar 1000mg/m^2 infusion, or paclitaxol 175mg/m^2 infusion for 180 minutes, at intervals of 3～4 weeks. Result： 38 patients altogether chemotherapy 98 treatment courses, the average each example patient chemotherapy 2.57 treatment courses, PR13 （34.2%）, does no CR patient, incidence of leucopenia approximately 36.8% （14/38）, nopatients have renal toxicity. Conclusion： Nedaplatins effect is similar to cisplatin in treating non - small cell lung cancer, digestive reaction and renal toxicity is mild, is worth studying and popularizing.
出处
《河北医学》
CAS
2006年第7期622-624,共3页
Hebei Medicine
关键词
奈达铂
非小细胞肺癌
化疗
Nedaplatin
Non-small cell lung cancer
Chemotherapy
